Oxford Asset Management’s Heron Therapeutics HRTX Stock Holding History

Oxford Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-51,548	Closed	-$1.21M	–	700
2019 Q4	$1.21M	Buy	+51,548	New	+$1.14M	0.03%	746
2019 Q2	–	Sell	-61,998	Closed	-$1.51M	–	1824
2019 Q1	$1.51M	Buy	+61,998	New	+$1.62M	0.03%	724
2018 Q4	–	Sell	-18,053	Closed	-$566K	–	1913
2018 Q3	$566K	Buy	18,053 +8,783	+95%	+$327K	0.01%	1266
2018 Q2	$374K	Buy	+9,270	New	+$295K	0.01%	1439
2016 Q1	–	Sell	-80,036	Closed	-$2.21M	–	840
2015 Q4	$2.21M	Buy	+80,036	New	+$2.14M	0.05%	372

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oxford Asset Management's HRTX Position: Q1 2020 in Review

Oxford Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 51,548 shares — an estimated $1.21M sold.

Oxford Asset Management first reported a position in HRTX in Q4 2015 and held it in 5 quarters. The position peaked at $2.21M in Q4 2015. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Oxford Asset Management reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 51,548 Heron Therapeutics shares in Q1 2020, an estimated $1.21M.
Oxford Asset Management first reported a position in Heron Therapeutics in Q4 2015 and held it in 5 quarters.
Oxford Asset Management's Heron Therapeutics position peaked at $2.21M in Q4 2015.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.